post of the day

featured

Association of British Neurologists (ABN) meeting 2022

The ABN meeting took place this year in Harrogate, North Yorkshire and was well attended by neurologists and pharma colleagues alike. The Town is very familiar to MD (aka. Prof David Baker) who has come through it all without any visible misgivings. The meeting was packed with a lot of discussions on current and upcoming MS clinical trials, service provision in the UK and treatment guidelines on...

Latest stories

There is more to SPMS than active inflammation

ASCEND is a clinical trial of natalizumab in secondary progressive MS and based on looking at EDSS (a walking scale at the point tested) the trial failed and natalizumab was, in the eyes of many neuros, chucked on the maggot pile as far as treating progressive MS has been concerned. However, this view has been challenged based on response to changes in hand function and in relation to effects on...

It’s Not Cancer? Phew, That’s OK Then. 

By Dominic Shadbolt (theMSguide.com)  This is a follow-up to an article recently published on the MS Research Blog that you can read here. Like much of life, people like the simple binary explanations. A is bad and B is good. Multiple Sclerosis has been tarred by this need for simplification. Cancer kills, MS doesn’t is the rough equivalent. Now the requirement for understanding the...

Thyroid problems post alemtuzumab in MS, the endocrinologists take on this

Thyroid dysfunction is the commonest treatment related side effect after alemtuzumab. Alemtuzumab targets CD52 on the surface of T and B cells taking them out of circulation. The precursor cells to the adult T and B cells are left intact because of their lack of the CD52 surface marker. After cell depletion, which occurs very quickly there is then a period of immune reconstitution resulting in...

Countdown to Swansea

Some of you feel they are no more than talking shops, but conversations at conferences sometimes do produce results, for example a new trial – AttackMS is such a product. The next domestic highlight in any UK MSologists’ diary is the MS Society’s MS Frontiers meeting hosted on the Bay Campus of Seaside University Swansea, on 6th and 7th of July. I provided some details back in...

This is Spinal Tap…Again

This study is about hunting for antibody bands in lumbar punctures and suggests there is limited value in repeat assays….This may be the case for bands but looking for other things like neurofilaments to indicate worsening Repeated lumbar puncture in search of oligoclonal bands – What is the yield? Mermelstein M, Naftali J, Wilf-Yarkoni A, Lotan I, Hellmann MA, Steiner I.J Neurol Sci...

The Real MS has sat down again?

What is going on in MS? One person has an idea, another one has a different idea. What is the Real MS? We have heard this many, many times. Outside in (immune system issue comes from the outside -in) or the problems starts on the inside (inside out). I have long said this is a sterile argument as the key events have probably occurred before we even know MS has started so to look ages later is...

Predicting worsening

To those familiar to the blog they will know what neurofilament is but simply put is is a structural protein only found inside nerves. So if you can detect it in biological fluids it says a nerve has got damaged. This study says neurofilament levels in blood predict a worse course. This is abit NSS because if disability is a product of previous nerve damage, then if you can measure markers of...

Predicting cladribine activity

As you know we have been called the Clad Lads and so it is appropriate for us to see what this real world cladribine says. In addition if you are eligible for Chariot MS please consider volunteering ChariotMS – Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (ChariotMS). NCT04695080 What does this study say when they are looking at the real world data? I will...

Project hindsight: Dutch aHSCT awakening! 

Lately, there has been a lot of of debate about the position of aHSCT in the MS treatment field. Evolving insights fuelled by the actions of MS charities and the conclusions of the recent ECTRIMS focused workshop on aHSCT have triggered the Dutch Association of Neurologists to change their point of view on the matter, namely that there is no role for aHSCT in the context of MS treatment. In May...

Will the real MS stand up, sit down and stand up again.

I’m not going to comment much on this paper but there is a debate about the “real MS” and the cause of progression. Some people ask “can the Real MS stand-up?” because they are not sure what drives MS. One school of thought is that there is something fundamentally different from what drives relapsing MS, but another school of thought is that it can be a consequence...

Translate

Categories

Recent Posts

Recent Comments

Archives